British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
Authors: Smith, C.H.; Anstey, A.V.1; Barker, J.N.W.N.; Burden, A.D.2; Chalmers, R.J.G.3; Chandler, D.4; Finlay, A.Y.5; Grifitths, C.E.M.3; Jackson, K.; McHugh, N.J.6; McKenna, K.E.7; Reynolds, N.J.8; Ormerod, A.D.9
Source: British Journal of Dermatology, Volume 153, Number 3, September 2005 , pp. 486-497(12)
Publisher: Blackwell Publishing
Keywords: biologics; efalizumab; etanercept; guideline; infliximab; psoriasis
Document Type: Research article
DOI: 10.1111/j.1365-2133.2005.06893.x
Affiliations: 1: Department of Dermatology, Royal Gwent Hospital, Newport NP20 2UB, U.K. 2: Department of Dermatology, Western Infirmary, Glasgow G11 6NT, U.K. 3: The Dermatology Centre, Hope Hospital, Salford, Manchester M6 8HD, U.K. 4: Psoriatic Arthropathy Alliance, PO Box 111, St Albans AL2 3JQ, U.K. 5: Department of Dermatology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, U.K. 6: Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath BA1 1RL, U.K. 7: Department of Dermatology, Belfast City Hospital, Belfast BT9 7AB, U.K. 8: Department of Dermatology, University of Newcastle Medical School, Newcastle upon Tyne NE2 4HH, U.K. 9: Department of Dermatology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, U.K.

Click here for Page Help